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1  | INTRODUCTION
For	more	than	half	a	century	after	the	first	case	series	of	placenta	
accreta was reported in 1937,1	 the	main	 and	often	only	 approach	
to	management	 was	 a	 cesarean	 hysterectomy.	 This	 approach	 had	
the	advantage	of	reducing	the	immediate	risks	of	major	hemorrhage	
associated	with	accreta	placentation	at	 a	time	when	 there	was	no	
access to blood transfusion.
Over	 the	 last	 two	decades,	 a	variety	of	 conservative	options	 for	
the	management	 of	 placenta	 accreta	 spectrum	 (PAS)	 disorders	 have	
evolved,	each	with	varying	rates	of	success,	and	peripartum	and	second-
ary	complications.2–4	In	a	recent	systematic	review	and	meta-	analysis	
of	the	outcome	of	placenta	previa	accreta	diagnosed	prenatally,	208	
out	of	232	(89.7%)	cases	had	an	elective	or	emergent	cesarean	hyster-
ectomy.5	As	a	result	of	a	lack	of	randomized	clinical	trials,	the	optimal	
management	of	PAS	disorders	 remains	undefined	and	 is	determined	
by	the	capacity	to	diagnose	invasive	placentation	preoperatively,	local	
expertise,	depth	of	villous	invasion,	and	presenting	symptoms.4
In	 cases	 of	 high	 suspicion	 for	 PAS	 disorders	 during	 cesarean	
delivery,	the	majority	of	members	of	the	Society	for	Maternal-	Fetal	
Medicine	 (SMFM)	 proceed	with	 hysterectomy	 and	 only	 15%–32%	
report	conservative	management.6,7	However,	there	is	considerable	
practice	variation	reported	on	aspects	of	care	around	delivery	and	
hysterectomy	 by	 both	 obstetricians	 and	 maternal-	fetal	 medicine	
specialists.6,8	 There	 is	 also	 wide	 variation	 between	 high-	income	
countries and low- and middle- income countries owing to limited 
or	 no	 access	 to	 specialist	 care	 and	 essential	 additional	 treatment,	
such	as	blood	products	 for	 transfusion.	Hysterectomy	 remains	 the	
definitive	 surgical	 treatment	 for	 PAS	 disorders,	 especially	 for	 its	
invasive	forms,	and	a	primary	elective	cesarean	hysterectomy	is	the	
safest	and	most	practical	option	for	most	 low-	and	middle-	income	
countries	where	diagnostic,	follow-	up,	and	additional	treatments	are	
not	available.	In	this	chapter,	we	review	the	evidence-	based	data	on	
nonconservative	 surgery	 (i.e.	 cesarean	hysterectomy)	 for	 the	man-
agement	of	PAS	disorders.
2  | PREPARATION FOR THE  
OPERATIVE MANAGEMENT OF 
INVASIVE PLACENTATION
Cesarean	hysterectomy	in	the	setting	of	PAS	disorders	can	be	chal-
lenging	because	multiple	cesarean	deliveries	often	present	with	pelvic	
adherences,	a	thin	and	hypervascular	lower	uterine	segment,	a	bulky	
in-	situ	placenta,	 and	deep	pelvis	neovascularization,	as	well	 as	pos-
sible invasion to bladder, bowel, cervix, and parametrium in cases of 
placenta percreta.
The	main	risk	associated	with	any	form	of	PAS	disorder	is	massive	
obstetric	hemorrhage,	which	leads	to	secondary	complications	includ-
ing	 coagulopathy,	multisystem	organ	 failure,	 and	death9–20	 (Table	1).	
Surgical	risks	increase	with	the	depth	of	placental	invasion,	with	women	
presenting	 with	 placenta	 percreta	 more	 likely	 to	 require	 additional	
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blood	products,	 have	urologic	 injury,	 and	 require	 intensive	 care	unit	
admission	than	women	with	placenta	creta	(vera	or	adherenta).10,21,22
Accurate prenatal diagnosis, careful planning, and close commu-
nication	 are	 essential,	 including	 the	 creation	 of	 specialized	 surgical	
teams	to	execute	a	safe	care	plan	for	patients	with	PAS	disorders.
2.1 | Multidisciplinary team care
Multiple	 retrospective	 cohort	 studies	 of	 PAS	 disorders	 have	 docu-
mented	reduced	maternal	morbidity	when	care	is	provided	in	centers	
of	excellence	(CoE).11,15,17,23	The	hallmark	features	of	a	CoE	are	listed	
in Table 2.24	While	the	exact	components	of	care	plans	may	vary	from	
center	to	center,	the	common	aspects	remain	a	dedicated	care	plan	
and	a	multidisciplinary	team	(MDT)	with	surgical	expertise	capable	of	
managing	the	full	spectrum	of	accreta	complexity.
Recent	cohort	studies	have	shown	that	women	managed	by	MDT	
care	were	less	likely	to	require	large-	volume	blood	transfusion,	inten-
sive	care	unit	admission,	and	reoperation	within	7	days	of	delivery	com-
pared	with	management	by	standard	obstetric	care	without	a	specific	
protocol11,15,17,23	 (Table	3).	 Each	 component	 within	 the	 care	 plan	 is	
important.	In	a	Canadian	prospective	chart	review	of	33	patients	within	
a	CoE,	stepwise	increasing	use	of	MDT	components	was	significantly	
associated	with	 a	 reduction	 in	 composite	morbidity,9	which	 demon-
strates	the	additive	value	of	each	component	of	care.	A	sufficient	vol-
ume	of	cases	per	year	to	maintain	the	experience	of	the	MDT	is	crucial.
Surgical	 expertise	 in	 complex	 pelvic	 surgery	 is	 a	 core	 principle	
for	management	of	PAS	disorder	cases.	A	single-	center	 retrospective	
cohort	of	98	cases	of	histologically	confirmed	PAS	disorders	showed	
that	the	cases	where	a	gynecologic	oncologist	was	on	standby	but	not	
in	the	operating	room	had	both	higher	blood	loss	and	transfusion	rates	
than	when	oncology	was	present	from	the	onset.25	This	supports	the	
early	presence	of	an	expert	with	specific	experience	in	cesarean	hyster-
ectomy	for	PAS	disorders	and	in	particular	in	cases	of	placenta	percreta.	
This	is	usually,	but	not	always,	a	gynecological	surgeon	and	is	depen-
dent	on	the	MDT	make-	up	of	the	team.	Within	this	context,	if	a	“call	if	
needed”	approach	is	not	acceptable	then	the	availability	of	expert	MDT	
care	at	all	times	must	be	ensured.	This	approach	is	pivotal	in	cases	of	
placenta	percreta	with	invasion	of	the	surrounding	pelvic	organs	such	
as	the	bladder.	Using	data	from	the	UK	Obstetric	Surveillance	System	
registry,	 a	 population-	based	 cross-	sectional	 study	 found	 that	 nearly	
half	(49%)	of	the	women	requiring	a	massive	transfusion	present	with	a	
PAS	disorder	and	34%	of	those	present	outside	working	hours.26
Overall,	 MDTs	 demonstrate	 ongoing	 improvements	 in	 patient	
safety	with	increasing	experience	and	reflective	changes	in	care	plans.	
One	 study	 including	 a	 total	 118	 PAS	 disorder	 cases	 that	 compared	
two	sequential	time	periods	reported	reductions	 in	estimated	blood	
TABLE  1 Complications	associated	with	surgery	for	placenta	
accreta	spectrum	(PAS)	disorders.
Complications
Median	estimation	of	blood	loss 2–3	L
Median units of packed red blood cells transfused 3.5–5.4	L
Large-	volume	blood	transfusions	(>10	L) 5%–40%
Injury to bladder 7%–48%
Injury to ureter 0–18%
Admission to intensive care unit 15%–66%
Bowel	injury/obstruction 2%–4%
Venous	thromboembolism 4%
Surgical	site	infection 18%–32%
Reoperation 4%–18%
Maternal mortality 1%–7%
TABLE  2 Components	of	multidisciplinary	team	care	within	Centers	of	Excellence	for	placenta	accreta	spectrum	(PAS)	disorders.
Component
Universal	access	to	multidisciplinary	team	care 24/7	access	to	the	care	team	to	enact	care	plan	in	urgent/emergent	situations
Standard	care	plan Consistent	and	standardized	care	plan	should	be	established,	this	can	be	aided	by	use	
of	checklists	to	guideprenatal,	intrapartum	and	postpartum	care
Radiologic	expertise	for	diagnosis Ultrasound and/or MRI
Experienced obstetrician/maternal–fetal medicine specialist For	prenatal	diagnosis,	prepartum,	intrapartum,	and	postpartum	management
Surgical	Eexpertise	for	complex	surgery	(Ggynecologic	
oncology,	pelvic	surgeon,	urogynecologist)
Skills	for	retroperitoneal	dissection,	ureterolysis,	internal	iliac	artery	ligation,	ureteral	
stent placement
Anesthetist	(obstetrical	or	trauma) Experienced	in	management	of	massive	hemorrhage	as	well	as	perioperative	
management of pregnant women
Neonatal intensive care unit and neonatalogists To	manage	both	planned	late	preterm	delivery	and	unplanned	preterm	delivery
Adult intensive care unit and intensivists Surgical	and	medical	intensive	care	unit	for	postoperative	care	as	required
Massive transfusion capacity Access to blood products/bank, massive transfusion protocol, transfusion medicine 
specialists/blood	bank	pathologists
Additional	surgical	expertise	when	required:	urology,	
vascular surgery, general surgeon, trauma surgeon
Management	of	complications:	ureteral	reimplantation,	bowel	resection,	
vascular injury
Interventional	radiology For	possible	placement	of	intravascular	balloons	or	postoperative	selective	arterial	
embolization
Cell saver and perfusionists If	available,	may	be	cost-	effective	depending	on	frequency	of	transfusion	of	
allogenic blood
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loss,	proportion	of	women	receiving	blood	transfusions,	proportions	
of large- volume blood transfusions, and use of massive blood trans-
fusion	protocols	over	time	within	a	well-	established	MDT.27	However,	
the	improvements	in	maternal	morbidity	were	only	demonstrated	for	
increta	and	percreta	cases,	highlighting	the	importance	of	MDT	expe-
rience	with	the	complex	and	more	invasive	forms	of	PAS	disorders.
Despite	 the	 clear	 benefits	 of	 decreased	 maternal	 morbidity,	 no	
benefit	 or	 adverse	 effect	 on	 neonatal	 outcomes	 has	 been	 demon-
strated	with	MDT	care	for	PAS	disorders	in	CoE.11,15	Operative	times	
with	MDTs	may	 be	 significantly	 longer.	 Surgeries	 in	 a	 single	 center	
were	 260	±	68	minutes	with	 the	 team	 and	 181	±	57	minutes	 in	 the	
absence	 of	 the	MDT,	 likely	 as	 a	 result	 of	 introducing	more	 aspects	
of care.23	It	is	also	possible	that	the	MDT	becomes	involved	with	the	
more	complex	cases	that	simply	require	more	time	to	set	up	and	per-
form.	These	longer	operating	times	may	affect	resource	utilization	and	
are not available in low- income and most middle- income countries.
2.2 | Timing of delivery
Studies	 reporting	 actual	 timing	 of	 delivery	 are	 conflicting	 and	 the	
optimal	timing	of	delivery	for	women	with	suspected	PAS	disorders	
remains	uncertain.	At	present,	there	remains	insufficient	evidence	to	
determine	the	exact	optimal	age	for	planned	delivery.	Different	cent-
ers	have	published	varying	protocols	with	recommendations	ranging	
from	34	to	36	weeks	to	36–38	weeks	of	gestational	age	for	planned	
delivery.9–11,15,18,28,29	 The	 majority	 of	 cases	 of	 PAS	 disorders	 are	
now	associated	with	placenta	previa,13,14	and	thus	as	gestational	age	
increases	the	likelihood	of	major	prepartum	hemorrhage	increases.
Scheduled	 nonemergent	 deliveries	 result	 in	 a	 significant	 reduc-
tion	 in	 maternal	 morbidity	 due	 to	 PAS	 disorders.	 Complications	
related	to	blood	loss	are	lower	in	nonemergent	compared	with	emer-
gent deliveries.12,13,16	 This	 knowledge	 has	 led	 to	 the	 scheduling	 of	
surgical	 interventions	 with	 planned	 late	 preterm	 (35–36	weeks)	 or	
early	term	(37	weeks)	delivery	as	a	mechanism	to	avoid	the	need	for	
emergency	surgery.	An	MDT	care	plan	that	included	planned	delivery	
at	 34–35	weeks	 demonstrated	 a	 reduction	 in	 emergency	 deliveries	
from	23%	to	64%	with	no	adverse	effects	on	neonatal	outcomes.11
A decision tree analysis comparing strategies for delivery of women 
with	placenta	previa	accreta	from	34	to	39	weeks	demonstrated	that	
under	a	variety	of	circumstances,	delivery	at	34	weeks	after	adminis-
tration	of	corticosteroid	for	 lung	maturity	may	be	the	preferred	tim-
ing	 as	 reflected	 in	 quality-	adjusted	 life	years.30	There	 is	 no	 role	 for	
assessing	 fetal	 lung	maturity	with	amniocentesis	and	 little	benefit	 is	
gained from expectant management beyond 37 weeks. Modelling did 
indicate	that	when	the	risk	of	prepartum	hemorrhage	is	low,	delivery	
at	37	weeks	may	be	optimal.
A	retrospective	cohort	study	of	77	women	with	suspected	PAS	dis-
orders	 found	 that	women	who	delivered	prior	 to	 a	 planned	delivery	
date	were	significantly	more	likely	to	have	had	prior	prepartum	hemor-
rhage	and	uterine	activity	compared	with	women	who	had	a	scheduled	
delivery.	Each	episode	of	prepartum	hemorrhage	is	associated	with	an	
increased	risk	of	unscheduled	delivery	(aOR	3.8,	95%	CI	1.8–7.8).	The	
interval	to	delivery	further	decreases	when	bleeding	is	associated	with	
preterm	premature	rupture	of	membranes	(PPROM).	Thus	the	women	
who	may	 benefit	 the	most	 from	 a	 strategy	 of	 planned	 late	 preterm	
delivery	are	those	with	a	history	of	episodes	of	prepartum	hemorrhage,	
PPROM,	or	uterine	contractions.28,29	The	corollary	remains	that	women	
who	 are	 stable	with	 no	 prepartum	 hemorrhage,	 PPROM,	 or	 uterine	
contractions	may	be	considered	for	planned	delivery	at	36–37	weeks.
Overall,	in	women	with	episodes	of	prepartum	hemorrhage,	especially	
recurrent,	PPROM,	and	contractions,	planned	preterm	delivery	may	be	
warranted.	Risks	of	urgent	delivery	to	maternal	health	must	be	balanced	
with	the	neonatal	complications	associated	with	late	preterm	delivery.
2.3 | Maximizing hemoglobin preoperatively
Owing	to	the	anticipated	risk	of	hemorrhage	at	delivery,	preoperative	
optimization	of	hemoglobin	 is	essential.	The	prevalence	of	anemia	 in	
TABLE  3 The	impact	of	multidisciplinary	team	(MDT)	care	on	the	management	of	placenta	accreta	spectrum	(PAS)	disorders.
Author
Cohort 
size (n) Study design Comparator Improvements with MDT care vs control
Eller et al.17 
USA
141 Retrospective	
cohort	study
79	MDT	centers	(2	hospitals) 
62	standard	obstetric	(hospitals)	
Centers	(26	hospitals)
Large-	volume	transfusions	(4	or	more	units)	43%	vs	61%	(P=0.031) 
Reoperation	within	7	d	3%	vs	36%	(P<0001) 
Composite	early	morbidity	47%	vs	74%	(P=0.026) 
Odds	ratio	of	composite	early	morbidity	0.22	(0.07–0.70)
Al-	Khan	et	al.,15 
USA
67 Retrospective	
cohort	study
Before	and	after	institution	of	a	
management protocol in single 
institution,	early	cohort	25,	late	
cohort	42
Estimated	blood	lossreduced	by	48%	(P<0.001) 
Intraoperative	packed	red	blood	cell	transfusion	reduced	
by	40%	(P<0.01) 
Total	transfused	packed	red	blood	cells	reduced	by	50%	(P<0.01) 
Intensive	care	unit	admissions	reduced	by	>50%	(P<0.01)
Shamshirsaz	
et al.,11	USA
90 Retrospective	
cohort	study
Before	and	after	formal	program	
of standardized MDT in 3 
tertiary	hospitals 
57 MDT, 33 non- MDT
Less	urgent	delivery	with	MDT	23%	vs	64%	(P=0.001) 
Less	estimated	blood	loss	with	MDT	2.1	L	(0.5–18	L)	vs	3	L	
(0.8–14)	(P=0.008)
Smulian	et	al.,23 
USA
47 Retrospective	
cohort	study
Before	and	after	MDT	implemented,	
single	institution 
19 MDT, 28 non- MDT
Less	blood	loss	with	MDT	1.2	L	vs	2.5	L	(P=0.009) 
Less	administration	of	blood	products	47.4%	vs	85.7%	(P=0.005) 
Higher	intraoperative	lowest	mean	arterial	pressures	57	mm	Hg	
vs	48	mm	Hg	(P=0.002)
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pregnancy	may	be	as	high	as	38%,	with	the	majority	caused	by	iron	defi-
ciency.	Women	in	low-	income	countries	are	at	even	higher	risk	due	to	
malnutrition	and/or	pre-existing	diseases	such	as	malaria	or	sickle	cell	
anemia.	Prenatal	correction	of	iron	deficiency	anemia	is	an	important	
consideration	 in	management	 of	 PAS	 disorders.	 Oral	 or	 intravenous	
iron	therapy	if	available	should	be	administered	if	iron	deficiency	ane-
mia	is	confirmed.	Intravenous	iron	therapy	is	safe	in	pregnancy	and	has	
been	demonstrated	to	correct	anemia	in	more	women	than	oral	iron.31 
In	addition,	efficacy	with	a	single	dose	intravenous	therapy	is	possible.32 
There	 are	 some	 centers	 where,	 resources	 permitting,	 erythropoietin	
therapy	is	combined	with	concomitant	intravenous	iron	treatment.
2.4 | Minimizing unintended urologic injury
In	a	systematic	review	of	surgical	techniques	used	for	PAS	disorders,	
the	overall	rate	of	unintentional	urinary	tract	injury	at	peripartum	hys-
terectomy	was	 29%	 (83/285)—higher	 than	 rates	 for	 hysterectomies	
for	other	gynecologic	 indications.33	Seventy-	eight	percent	of	 injuries	
involve	 the	bladder,	whereas	17%	 involve	 the	ureter.33	Modification	
of	surgical	technique	has	the	ability	to	reduce	urinary	tract	injury	com-
pared	with	standard	hysterectomy.33	 In	particular,	placement	of	ure-
teric	stents	preoperatively	can	reduce	the	risk	of	urinary	 tract	 injury	
from	33%	 to	6%.33 At ureteric stent placement, cystoscopic assess-
ment	 can	also	evaluate	 for	evidence	of	bladder	 invasion	by	 the	pla-
centa. Inconsistent use of stents across studies is ascribed to surgeon 
preference.19,33	Ureteral	stents	or	catheters	are	more	commonly	used	
in	 the	USA	where	26.2%–35%	of	maternal	 fetal	medicine	specialists	
and	26.3%	of	ACOG	fellows	use	them	in	the	management	of	PAS	disor-
ders.6–8	Opening	the	retroperitoneal	space	and	visualizing	the	ureters	
can	be	helpful	and	may	prevent	inadvertent	damage	to	the	ureter.16
Clinical	symptoms	of	bladder	invasion	are	rare.	In	a	review	of	the	
published	literature	including	20	cases	of	bladder	invasion,	only	a	quar-
ter	presented	with	gross	hematuria.34	Hence,	most	commonly,	preoper-
ative	cystoscopy	and	the	placement	of	ureteral	stents	are	recommended	
when	urinary	bladder	invasion	is	suspected	on	prenatal	imaging.11,15,19 
Greater	depth	of	placental	invasion	is	associated	with	urologic	injury.22 
For	placenta	percreta	with	bladder	involvement,	some	authors	recom-
mend	deliberate	cystotomy,	identification	of	the	percreta	villous	tissue,	
and	excision	of	the	involved	bladder	rather	than	difficult	dissection.11,35
The	 other	 major	 factor	 to	 avoid	 urinary	 tract	 injury	 is	 to	 avoid	
major	intraoperative	bleeding,	which	will	both	limit	visibility	and	create	
urgency	for	bladder	dissection.	Urologic	injuries	have	been	shown	to	
increase	when	intraoperative	blood	loss	is	greater.22	Dissection	of	the	
bladder	first,	prior	to	delivery,	has	been	shown	to	allow	sufficient	time	
to	identify	and	create	the	vesicouterine	plane	before	an	intraoperative	
bleed,	which	will	make	the	identification	of	the	different	tissues	diffi-
cult.33	In	particular,	in	some	cases	of	placenta	percreta	the	abundance	
of	 the	newly	 formed	vessels	might	complicate	 the	dissection	of	 the	
bladder and cause profuse bleeding.
In	those	cases	where	there	is	extensive	anterior	and	lateral	invasion	
or	bulging	of	the	thinned-	out	uterus	into	the	lateral	pelvic	sidewalls,	
adopting	a	posterior	approach	may	allow	stepwise	devascularization	
of	the	uterus	and	may	aid	in	the	hysterectomy.36
Putting	patients	in	the	lithotomy	position	in	stirrups	improves	eval-
uation	of	 the	 amount	 of	 intraoperative	bleeding.	 Filling	 the	bladder	
before	the	surgical	procedure	helps	in	the	dissection	of	the	lower	seg-
ment	 and	 allows	 for	 an	 easier	 cystotomy,	when	needed,	 and	better	
detection	of	the	cervix	during	total	hysterectomy.16
3  | INTRAOPERATIVE CONSIDERATIONS
3.1 | Anesthesia
The	 choice	 of	 anesthesia	 technique	 for	 cesarean	 delivery	 where	
there	 is	a	suspected	PAS	disorder	with	high	risk	of	significant	hem-
orrhage	must	be	made	by	the	attending	anesthesia	team.	This	deci-
sion	between	general	and	neuraxial/regional	anesthesia	can	be	aided	
through	active	consultation	with	the	wider	MDT.
There	are	several	factors	to	consider	that	can	influence	this	deci-
sion	 (Box	 1).	 Historically,	 most	 patients	 with	 PAS	 disorders	 were	
managed	conservatively	with	general	anesthesia,	as	described	in	a	ret-
rospective	study	of	26	maternity	hospitals	in	Israel.37 Recently, greater 
experience	has	permitted	more	frequent	use	of	epidural	with	or	with-
out	spinal.	When	managed	appropriately	and	in	an	elective	situation,	
most	patients	can	tolerate	both	prolonged	and	extensive	surgery	with	
significant	associated	blood	loss	using	these	techniques.38–40
The	 international	 literature	 reports	an	8%–45%	risk	of	 the	need	
to	convert	from	regional	to	general	anesthesia	for	cases	of	PAS	disor-
ders.40–43	Most	of	these	occur	when	there	is	no	prior	suspicion	of	PAS	
disorders	and	the	diagnosis	is	made	intraoperatively.	The	highest	rates	
of	 conversion	 appear	 to	 occur	 in	 low-	income	 countries,	which	 also	
have	higher	rates	of	reported	blood	loss;	therefore,	general	anesthesia	
may	be	the	initial	method	of	choice	in	this	context.41
Several	 studies	 have	 reported	 decreased	 hemorrhage-	related	
morbidity	 and	 blood	 transfusion	 requirements	 at	 cesarean	 delivery	
Box 1 Factors to consider in selection of anesthesia for 
placenta accreta spectrum (PAS) disorders.
Criteria for consideration
Patient	preference
Body	habitus	(body	mass	index,	potentially	difficult	patient	airway)
American	Society	of	Anesthesiologists	Score
Available resources
Anesthetist	experience
Regional	anesthesia	effectiveness
State	of	emergency
Hemodynamic	stability
Ability	to	manage	patient	in	hypovolemic	shock
Ability	to	perform	a	rapid	emergent	tracheal	intubation
Patient	co-	morbidities
Potential	complications
Secondary	benefits,	i.e.	patient-	controlled	epidural	anesthesia	for	
postoperative	pain	management	with	midline	laparotomy
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with	 regional	 compared	with	 general	 anesthesia.44,45	 Of	 these,	 one	
randomized	 clinical	 trial	 was	 specifically	 designed	 to	 study	 women	
with	placenta	previa	including	accreta,	and	while	it	demonstrated	that	
blood	transfusion	requirements	were	greater	in	the	general	anesthe-
sia	group,	 there	was	no	significant	difference	 in	 reported	blood	 loss	
overall.44	No	 significant	difference	 in	blood	 loss	or	volume	of	blood	
transfused	between	 regional	and	general	 anesthesia	was	 found	 in	a	
recent	retrospective	cohort	of	50	cases	of	placenta	accreta	managed	
by a single Canadian CoE.43
Neonatal	 outcomes,	 in	 particular	 neonatal	 respiratory	 complica-
tions,	appear	to	be	improved	with	the	use	of	regional	compared	with	
general	anesthesia,	primarily	through	the	avoidance	of	volatile	agents	
crossing	the	placenta.43
3.2 | Type of incisions for access
Avoiding	 the	 placenta	 at	 planned	 cesarean	 hysterectomy	 reduces	
blood	 loss;	 therefore,	 the	 abdominal	 incision	 must	 allow	 sufficient	
access	to	the	uterus	to	choose	a	location	for	hysterotomy	above	the	
upper	placental	margin.	Preoperative	or	intraoperative	ultrasound	can	
allow	the	team	to	visualize	the	upper	placental	margin,	which	facili-
tates	planning	both	the	abdominal	and	uterine	incision.15,46
A	low	transverse	skin	incision	that	allows	access	to	the	lower	half	
of	 the	uterus	may	be	 adequate	 if	 the	upper	margin	of	 the	placenta	
does	not	rise	into	the	upper	segment	of	the	uterus	and	no	hysterec-
tomy	 is	planned.	However,	 it	may	not	provide	sufficient	exposure	 in	
cases	of	placenta	percreta.	 If	 the	placenta	 is	anterior	and	extending	
toward	the	level	of	the	umbilicus,	and/or	a	hysterectomy	is	planned,	
a	 midline	 skin	 incision	 allows	 for	 a	 high	 upper-	segment	 transverse	
uterine	incision	above	the	upper	margin	of	the	placenta	or	more	com-
monly	a	fundal	transverse	hysterotomy	for	delivery	of	the	infant.	Thus,	
a	midline	incision	is	recommended	by	most	authors	for	PAS	disorders	
diagnosed	 prenatally	 or	 at	 the	 time	 of	 cesarean	 delivery.11,15,18,35,46 
The	Joel-	Cohen	incision	(4–5	cm	widths	above	the	pubic	symphysis)	
or	a	Cherney	extended	transverse	incision	(transection	of	the	rectus	
muscles	at	their	insertion	on	the	pubic	symphysis	or	a	vertical	incision	
of	the	fascia	abdominalis)	could	be	used	to	avoid	a	vertical	incision	or	
allow	increased	visibility,	but	there	are	no	available	data	on	the	use	of	
these	types	of	incisions	in	the	management	of	PAS	disorders.	Utilizing	
a	fetal	surgery	approach	to	hysterotomy,	with	either	a	uterine	stapler	
or	Smith-	Opitz	clamps,	can	reduce	blood	loss	dramatically	but	this	is	
only	available	in	a	few	CoE	in	high-	income	countries.
3.3 | Blood conservation techniques
3.3.1 | Tranexemic acid
Tranexamic	acid	is	a	widely	available	hemostatic	antifibrinolytic	agent	
that	inhibits	the	enzymatic	breakdown	of	fibrinogen	and	fibrin	by	plas-
min.	It	is	relatively	inexpensive	and	available	in	oral	tablet	and	injectable	
solution	forms	that	have	a	long	shelf	life	at	less	than	30°C.	Significant	
international	efforts	have	culminated	 in	several	studies	 investigating	
tranexamic	acid	in	obstetric	trauma	and	postpartum	hemorrhage.
Most recently, a large double- blind placebo- controlled trial 
recruited	over	20	000	patients	with	postpartum	hemorrhage	 to	 the	
WOMAN	 trial.47	 The	 study	 demonstrated	 that,	 compared	with	 pla-
cebo,	 tranexamic	 administration	 significantly	 reduced	 death	 due	 to	
massive	 obstetric	 hemorrhage	 without	 increasing	 rates	 of	 adverse	
events,	including	thromboembolism.
A	 recent	 meta-	analysis	 of	 nine	 trials	 involving	 2365	 patients	
confirmed	 these	 findings,	 demonstrating	 that	 the	 administration	 of	
tranexamic	acid	before	cesarean	delivery	 significantly	 reduces	 intra-	
and	postoperative	blood	loss	and	blood	transfusion	with	no	increase	
in	thromboembolic	events.48	After	this	analysis,	three	more	placebo-	
controlled	 trials	 have	 shown	 that	 tranexamic	 acid	 administration	
immediately	 before	 cesarean	 delivery	 significantly	 reduces	 reported	
intraoperative	 blood	 loss	 and	 postoperative	 declines	 in	 hemoglobin	
without	any	increase	in	adverse	maternal	or	neonatal	effects.49–51
No	trials	have	specifically	examined	the	role	of	tranexamic	acid	in	
the	surgical	management	of	PAS	disorders.	However,	the	quality	of	the	
evidence	on	postpartum	hemorrhage	justifies	its	use	in	the	manage-
ment	of	women	diagnosed	prenatally	or	presenting	with	PAS	disorders	
at	the	time	of	delivery.
3.3.2 | Balloon occlusion catheters
A	 large	 number	 of	 studies,	mostly	 retrospective,	 have	 evaluated	 the	
role	of	prophylactic	placement	of	balloon	occlusion	catheters	to	miti-
gate	bleeding	at	the	time	of	cesarean	hysterectomy	for	PAS	disorders,	
with	varied	results.52–73	These	devices	are	usually	inserted	by	specialist	
interventional	 radiologists	 into	 the	 aorta,	 common	 iliac,	 internal	 iliac,	
or	uterine	arteries	under	fluoroscopic	guidance	and	are	inflated	when	
hemorrhage	is	encountered.	Many	authors	have	advocated	their	use,	
claiming	 a	 decrease	 in	 blood	 loss	 and	 transfusion	 requirements,	 and	
improved	visualization	on	the	surgical	field.52–68	However,	other	stud-
ies	 fail	 to	demonstrate	any	benefit	and	criticize	 their	use.69–73	These	
authors	 claim	 that	 occlusive	 balloons	 cannot	 prevent	 catastrophic	
bleeding	since	the	blood	supply	to	the	pelvis	is	maintained	by	the	devel-
opment	of	rich	collaterals	during	pregnancy.73,74	In	fact,	they	postulate	
that	 the	empiric	 inflation	of	 these	balloons	 in	a	 relatively	dry	setting	
may	 actually	 exacerbate	 bleeding	 from	 such	 collaterals.71–74	 Finally,	
reports	of	vessel	rupture	and	thromboembolic	catheter-	related	compli-
cations	have	called	into	question	these	balloons’	risk–benefit	ratio.75–81
Well-	designed	 randomized	 controlled	 trials	 are	 needed	 to	 truly	
demonstrate	the	safety	and	efficacy	of	these	devices	and	to	establish	
whether	certain	subgroups	of	patients	with	PAS	disorders	would	derive	
more	benefit	(i.e.	more	invasive	placentation).82	Currently,	the	evidence	
available	is	insufficient	to	make	firm	recommendations	on	their	use.
3.3.3 | Internal Iliac artery ligation
Advantages	to	surgically	ligating	the	internal	iliac	arteries	are	similar	to	
those	for	balloon	occlusion	devices.	However,	with	the	proper	skillset,	
surgical	 internal	 iliac	 artery	 ligation	 has	 the	 added	 benefit	 of	 being	
available	in	low-	and	middle-	income	countries,	where	access	to	inter-
ventional	radiology	may	be	limited.
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Studies	 evaluating	 the	 safety	 and	 effectiveness	 of	 internal	 iliac	
artery	ligation	in	the	context	of	PAS	disorders	specifically	are	few.	In	a	
study by Grace Tan et al.,10	44%	of	patients	underwent	bilateral	inter-
nal	iliac	artery	ligation	prior	to	hysterectomy	for	placenta	accreta;	how-
ever,	transfusion	requirements	were	the	same	as	for	those	who	did	not	
under	ligation.10	In	a	smaller	study	of	23	cases,	15	of	whom	underwent	
internal	iliac	artery	ligation,	no	differences	in	mean	blood	loss	or	blood	
loss	greater	than	5	L	was	demonstrated	with	and	without	ligation.38
3.3.4 | Cell salvage
Autologous	cell	salvage	offers	a	way	to	minimize	allogenic	red	blood	
cell	transfusion	in	select	patients,	such	as	those	with	high	risk	of	mas-
sive	obstetric	hemorrhage,	 low	preoperative	hemoglobin	concentra-
tions,	rare	blood	types	(e.g.	Bombay),	and/or	those	who	refuse	such	
products	 including	 Jehovah’s	witnesses.83,84	Whilst	 cell	 salvage	 and	
retransfusion	are	viewed	as	relatively	expensive	and	 labor	 intensive,	
autologous cell salvage is now being adopted in many obstetric centers 
managing	PAS	disorders,	with	observational	studies	showing	improved	
outcomes	and	reduced	need	for	allogenic	blood	transfusion,	without	
an increase in adverse outcomes.84–86 Regarding cost analysis, a recent 
study	demonstrated	 that	 intraoperative	cell	 salvage	during	cesarean	
delivery	for	invasive	placentation	justified	its	use	where	the	probability	
of	requiring	packed	red	cell	transfusion	of	two	units	was	75%.87
It	is	important	that	suctioned	contaminants	are	kept	to	an	absolute	
minimum,	including	amniotic	fluid,	vernix,	microorganisms,	fetal	blood,	
and	exogenous	surgical	solutions	such	as	contemporary	hemostatics.88 
These	may	not	be	filtered	adequately	by	cell	salvage	equipment	and	
may	be	reinfused	directly	into	the	maternal	circulation	with	theoretical	
complications	including	embolism,	isoimmunization	and	thrombosis.
3.3.5 | Placental removal
Attempt	to	remove	an	undiagnosed	PAS	disorder	at	cesarean	deliv-
ery	is	known	to	lead	to	uncontrolled	hemorrhage.	These	risks	are	of	
particular	concern	when	the	delivery	takes	place	 in	an	environment	
with	no	emergency	access	 to	blood	bank	products	and	expertise	 in	
managing	PAS	disorders.	A	 retrospective	 study	of	 57	 cases	 of	 sus-
pected	PAS	disorders	demonstrated	significantly	reduced	short-	term	
morbidity	if	the	placenta	is	left	in	place	and	hysterectomy	performed	
electively	compared	with	attempting	to	remove	the	placenta	first.12 
In	 two	 additional	 retrospective	 cohorts,	 MDT	 care	 was	 associated	
with	 statistically	 lower	 rates	 of	 attempted	 placental	 removal	 and	 a	
reduction	in	blood	transfusion	rates,	large-	volume	blood	transfusion,	
and	estimated	blood	 loss	 for	PAS	disorders.17,23	However,	 in	 select	
patients,	intraoperative	inspection	of	the	uterus	at	cesarean	delivery	
may	allow	a	 trial	of	placental	 separation	 in	 suspected	cases	of	PAS	
disorders	without	increasing	morbidity.89	This	study	had	a	high	rate	of	
TABLE  4 Novel	techniques	for	cesarean	hysterectomy	in	patients	with	placenta	accreta	spectrum	(PAS)	disorders.
Author (n) Technique Description of Modification
Selman97;	Chile	(n=11) Posterior	retrograde	
hysterectomy	via	
pouch	of	Douglas
After	closure	of	hysterotomy,	uterus	is	exteriorized,	round	ligaments	are	divided,	retroperitoneal	
space dissected parallel to ureters and pelvic side wall vessels, utero- ovarian ligaments are 
divided bilaterally:
1.	Posterior	vaginal	fornix	exposed	with	sponge	stick	into	vagina	and	opened	transversely	below	
cervicovaginal	junction
2.	Vagina	circumscribed	with	clamps,	divided	and	ligated
3.	Ureters	identified,	dissected,	and	preserved	though	anterior	bladder	pillar
4.	Cervix	grasped,	pulled	up	behind	uterus
5.	Cardinal	ligaments,	uterosacrals,	and	bladder	pillars	are	sequentially	divided
6.	Vesicouterine	space	is	developed	until	bladder	detached	from	anterior	aspect	of	uterus	or	
cystotomy	and	resection	of	posterior	bladder	wall	if	placental	invasion
Shamshirsaz	et	al.11; 
USA	(n=57)
Modified	radical	
hysterectomy	
technique	and	use	of	
bipolar cautery device
Wide	margins	to	avoid	clamping	fragile/unsupported	vessels	and	or/thinned	myometrium
1.	Retroperitoneum	accessed	lateral	to	round	ligaments,	ureters,	internal	iliac	vessels	identified.	
Ureterolysis	performed	if	required.
2.	Uterus	separated	from	support	structures	with	wide	margin	on	broad	ligament
3.	Stepwise	devascularization	of	lower	uterine	segment
4.	 If	required	identification	and	ligation	of	superior	vesical	arteries
5.	 Intentional	cystotomy	and	excision	of	bladder	if	invasion
Belfort et al.90; 
USA	(n=3)
Linear	cutting	
staple device for 
hysterotomy
Midline	abdominal	incision,	uterus	exteriorized,	and	site	of	hysterotomy	identified	high	on	upper	
uterine segment of fundus
1. Uterine wall grasped to create fold of uterus
2.	Placement	of	4	full-thickness	sutures	in	box	patter	to	create	unperfused	area	of	upper	uterine	
segment
3.	Create	initial	entry	in	“box”	with	diathermy
4. Membranes dissected away from uterine wall digitally to create space for stapler
5.	 Linear	cutting	staple	device	inserted	and	deployed	1	to	3	times	as	required	to	create	
hysterotomy
Rossetti	et	al.91; Italy 
(n=49,	20	accreta)
Use of vessel- sealing 
devices	for	Peripartum	
Hysterectomy
Vessel sealing device used to facilitate surgery
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non-	confirmation	of	PAS	disorders	(45/99)	and	the	authors	provided	
no	details	of	the	depth	of	placental	invasion.
Response	to	a	survey	of	SMFM	providers	in	the	USA	indicated	that	
60%	attempt	placental	removal	with	PAS	disorders.	However,	providers	
with	more	experience	in	PAS	disorder	management	(as	assessed	by	the	
number	of	cases	per	year)	were	less	likely	to	attempt	placental	removal.6 
This	 is	 consistent	 with	 evidence	 from	 retrospective	 cohort	 studies,	
demonstrating	fewer	attempts	at	placental	removal	by	MDTs	in	CoE.
Overall,	in	the	setting	of	planned	immediate	hysterectomy	for	PAS	
disorders,	 no	 attempt	 at	 manual	 separation	 should	 be	 undertaken	
because	 leaving	 the	 placenta	 in	 situ	 is	 associated	with	 lower	 blood	
loss.	 If	 spontaneous	 partial	 separation	 occurs,	 management	 as	 per	
conservative	therapy	strategies	could	be	employed	if	the	accreta	por-
tion	of	the	placenta	is	limited	in	depth	and	laterally.	Therefore,	utero-
tonic	agents	are	not	administered	at	cesarean	hysterectomy	for	PAS	
disorders, unless placental removal is imminent35 or complete placen-
tal	separation	occurs	thus	ruling	out	PAS	disorders.
4  | TECHNIQUES FOR HYSTERECTOMY
4.1 | Total versus subtotal hysterectomy
Total	 hysterectomy	 is	 the	 recommended	 surgical	 method	 for	
	emergent	peripartum	hysterectomy	owing	 to	 the	potential	 risk	of	
malignancy	developing	 in	 the	cervical	 stump,	 the	need	 for	 regular	
cervical	 cytology,	 and	 other	 associated	 problems	 such	 as	 bleed-
ing	 or	 discharge.	 Proponents	 of	 subtotal	 hysterectomy	 report	
decreased	 blood	 loss,	 blood	 transfusions,	 perioperative	 complica-
tions,	and	shorter	operating	time.	However,	subtotal	hysterectomy	
may	not	be	effective	in	the	management	of	placenta	increta	or	per-
creta	 if	 cervical	 involvement	 is	 present	 and	 a	 total	 hysterectomy	
should	be	the	preferred	option	in	these	cases.	In	addition,	subtotal	
hysterectomy	 has	 not	 been	 shown	 to	 provide	 protection	 against	
	urinary	tract	 injury	compared	with	total	hysterectomy	in	surgeries	
for	PAS	disorders.33
The	 survey	 of	 SMFM	 specialists	 regarding	 their	management	 of	
PAS	disorders	was	split	with	regard	to	the	use	of	total	versus	subto-
tal	hysterectomy.	Just	over	half	(55%)	of	all	providers	performed	total	
procedures,	with	45%	reporting	use	of	supracervical	hysterectomy.6
4.2 | Other novel surgical techniques
Numerous	 centers	 have	 modified	 their	 surgical	 techniques	 in	 an	
attempt	 to	 minimize	 hemorrhage	 and/or	 to	 reduce	 unintentional	
injury	 to	 the	 urinary	 tract.11,36,90,91	 These	 techniques	 involve	 early	
devascularization	 and	use	of	 disposable	 devices	 such	 as	 stapling	or	
vessel	sealing	devices	(Table	4).
4.3 | Planned delayed hysterectomy
Planned	delayed	or	secondary	hysterectomy	is	an	alternative	“defini-
tive”	surgical	management	strategy	for	PAS	disorders.	Delayed	hys-
terectomy	may	be	undertaken	where	extensive	invasion	(percreta)	of	
surrounding	 structures	would	 render	 immediate	 cesarean	 hysterec-
tomy	extremely	 difficult.	Allowing	 some	 resorption	of	 the	placenta,	
decrease	 in	vascularity	and	 involution	of	the	uterus	 is	postulated	to	
facilitate	later	surgery.	However,	there	is	an	associated	risk	of	coagu-
lopathy,	hemorrhage,	 and	 sepsis	during	 the	 interim	period.	Patients	
must	be	compliant	with	follow-	up	and	resources	to	manage	patients	
urgently	if	complications	arise	should	be	available	24	hours	a	day.
Delayed	 hysterectomies	 are	 performed	 between	 3	 and	 12	weeks	
postpartum15,92,93 and many cases involve postdelivery uterine artery 
embolization	or	 internal	 iliac	 artery	 ligation	 and	 thus	 possible	 adverse	
effects	and	secondary	complications.15,92–94	The	estimated	blood	loss	in	
this	staged	surgical	approach,	 including	both	initial	delivery	and	subse-
quent	hysterectomy,	has	been	reported	to	be	less	or	similar	to	immedi-
ate surgery.15,92,94	Delaying	hysterectomy	in	complex	cases	may	reduce	
other	surgical	morbidity.	In	the	systematic	review	of	urinary	tract	injury	
rates	with	PAS	disorders,	there	were	no	reported	unintentional	urologic	
complications	in	nine	cases	of	delayed	hysterectomy;	however,	this	was	
not	statistically	significant	when	compared	with	immediate	management.	
Intentional	cystotomy	and	partial	cystectomy	were	still	required	in	three	
of	the	second	surgeries	(33%	of	the	cases).33
While	 traditionally	 these	 second	 surgeries	 involve	 a	 laparotomy,	
minimally	 invasive	 surgical	 approaches	 including	 robotics	have	been	
reported.92,94–96	This	approach	requires	advanced	skills	but	may	have	
enhanced	visualization	compared	with	laparotomy,	along	with	shorter	
recovery,	 although	 surgical	 times	 are	 quite	 prolonged	 (up	 to	 286–
330	minutes).92–96	 These	 techniques	 require	 care	 in	 CoE	with	 both	
advanced	 surgical	 programs	 and	 the	 capacity	 to	 manage	 emergent	
massive	obstetric	hemorrhage.
5  | RECOMMENDATIONS
Recommendations	 for	 the	 surgical	nonconservative	management	of	
PAS	disorders	are	given	in	Table	5.
CONSENSUS PANEL
Greg	 Duncombe	 (Australia	 and	 New	 Zealand),	 Philipp	 Klaritsch	
(Germany),	Frédéric	Chantraine	(Belgium),	John	Kingdom	(Canada),	
Lene	 Grønbeck	 (Denmark),	 Kristiina	 Rull	 (Estonia),	 Balkachew	
Nigatu	(Ethiopia),	Minna	Tikkanen	(Finland),	Loïc	Sentilhes	(France),	
Tengiz	 Asatiani	 (Georgia),	 Wing-	Cheong	 Leung	 (Hong	 Kong),	
Taghreed	 AIhaidari	 (Iraq),	 Donal	 Brennan	 (Ireland),	 Eiji	 Kondoh	
(Japan),	Jeong-	In	Yang	(South	Korea),	Muhieddine	Seoud	(Lebanon),	
Ravindran	 Jegasothy	 (Malaysia),	 Salvador	 Espino	 y	 Sosa	 (Mexico),	
Benoit	Jacod	(Netherlands),	Francesco	D’Antonio	(Norway),	Nusrat	
Shah	 (Pakistan),	 Dorota	 Bomba-	Opon	 (Poland),	 Diogo	 Ayres-	
de-	Campos	 (Portugal),	 Katarina	 Jeremic	 (Serbia),	 Tan	 Lay	 Kok	
(Singapore),	 Priya	 Soma-	Pillay	 (South	 Africa),	 Nataša	 Tul	 Mandić	
(Slovenia),	 Pelle	 Lindqvist	 (Sweden),	 Thora	 Berglind	 Arnadottir	
(Sweden),	 Irene	Hoesli	 (Switzerland),	Unnop	Jaisamrarn	 (Thailand),	
Amal	Al	Mulla	(United	Arab	Emirates),	Stephen	Robson	(UK),	Rafael	
Cortez	(Venezuela).
288  |     Allen eT Al.
CONFLICTS OF INTEREST
The	authors	have	no	conflicts	of	interest.
REFERENCES
	 1.	 Irving	FC,	Hertig	AT.	A	study	of	placenta	accreta.	Surg Gynec Obstet. 
1937;64:178–200.
	 2.	 Clausen	C,	 Lonn	 L,	 Langhoff-Roos	J.	Management	 of	 placenta	 per-
creta:	 A	 review	 of	 published	 cases.	 Acta Obstet Gynecol Scand. 
2014;93:138–143.
	 3.	 Amsalem	H,	Kingdom	JC,	Farine	D,	et	al.	Planned	caesarean	hysterec-
tomy	versus	“conserving”	caesarean	section	in	patients	with	placenta	
accreta. J Obstet Gynaecol Can. 2011;33:1005–1010.
	 4.	 Jauniaux	 E,	 Collins	 SL,	 Jurkovic	 D,	 Burton	 GJ.	 Accreta	 placen-
tation:	 A	 systematic	 review	 of	 prenatal	 ultrasound	 imaging	 and	
grading of villous invasiveness. Am J Obstet Gynecol. 2016;215: 
712–721.
	 5.	 Jauniaux	E,	Bidhe	A.	Prenatal	ultrasound	diagnosis	and	outcome	of	
placenta	previa	accreta	after	caesarean	delivery:	A	systematic	review	
and meta- analysis. Am J Obstet Gynecol. 2017;217:27–36.
	 6.	 Esakoff	TF,	Handler	SJ,	Granados	JM,	Caughey	AB.	PAMUS:	Placenta	
accreta	management	across	the	United	States.	J Matern Fetal Neonatal 
Med. 2012;25:761–765.
	 7.	 Jolley	JA,	Nageotte	MP,	Wing	DA,	Shrivastava	V.	Management	of	pla-
centa	 accreta:	A	 survey	of	Maternal-	Fetal	Medicine	 practitioners.	 J 
Matern Fetal Neonatal Med. 2012;25:756–760.
	 8.	 Wright	JD,	Silver	RM,	Bonanno	C,	et	al.	Practice	patterns	and	knowl-
edge of obstetricians and gynecologists regarding placenta accreta. 
J Matern Fetal Neonatal Med. 2013;26:1602–1609.
	 9.	 Walker	MG,	Allen	L,	Windrim	RC,	et	al.	Multidisciplinary	management	
of invasive placenta previa. J Obstet Gynaecol Can. 2013;35:417–425.
	10.	 Grace	Tan	SE,	Jobling	TW,	Wallace	EM,	McNeilage	LJ,	Manolitsas	T,	
Hodges	RJ.	Surgical	management	of	placenta	accreta:	A	10-	year	expe-
rience. Acta Obstet Gynecol Scand. 2013;92:445–450.
	11.	 Shamshirsaz	AA,	Fox	KA,	 Salmanian	B,	 et	 al.	Maternal	morbidity	 in	
patients	 with	 morbidly	 adherent	 placenta	 treated	 with	 and	 with-
out	a	standardized	multidisciplinary	approach.	Am J Obstet Gynecol. 
2015;212:218.e1–218.e9.
	12.	 Eller	AG,	Porter	TF,	Soisson	P,	Silve	RM.	Optimal	management	strate-
gies for placenta accreta. BJOG. 2009;116:648–654.
	13.	 Warshak	CR,	Ramos	GA,	Eskander	R,	et	al.	Effect	of	predelivery	diag-
nosis	 in	 99	 consecutive	 cases	 of	 placenta	 accreta.	Obstet Gynecol. 
2010;115:65–69.
	14.	 Wright	JD,	Pri-Paz	S,	Herzog	TJ,	et	al.	Predictors	of	massive	blood	loss	
in	women	with	placenta	accreta.	Am J Obstet Gynecol. 2011;205:38.
e1–38.e6.
	15.	 Al-Khan	A,	Gupta	V,	Illsley	NP,	et	al.	Maternal	and	fetal	outcomes	in	
placenta	accreta	after	 institution	of	team-	managed	care.	Reprod Sci. 
2014;21:761.
	16.	 Seoud	MA,	Nasr	R,	Berjawi	GA,	et	al.	Placenta	accreta:	Elective	ver-
sus emergent delivery as a major predictor of blood loss. J Neonatal 
Perinatal Med. 2017;10:9–15.
	17.	 Eller	AG,	Bennett	MA,	Sharshiner	M,	et	al.	Maternal	morbidity	in	cases	
of	placenta	accreta	managed	by	a	multidisciplinary	care	team	compared	
with	standard	obstetric	care.	Obstet Gynecol. 2011;117:331–337.
	18.	 Camuzcuoglu	A,	Vural	M,	Hilali	 NG,	 et	 al.	 Surgical	management	 of	
58	 patients	 with	 placenta	 praevia	 percreta.	Wien Klin Wochenschr. 
2016;128:360–366.
	19.	 Norris	BL,	Everaert	W,	Posma	E,	et	al.	The	urologist’s	role	in	multidisci-
plinary management of placenta percreta. BJU Int. 2016;117:961–965.
TABLE  5 Recommendations	for	the	surgical	nonconservative	management	of	placenta	accreta	spectrum	(PAS)	disorders.
Recommendations
Resource 
settings
Quality of evidence and 
strength of recommendation
Women	presenting	with	PAS	disorders	with	or	without	placenta	previa	should	have	their	delivery	
scheduled	in	a	Center	of	Excellence	with	a	dedicated	multidisciplinary	team	and	care	plan
High Moderate	and	Strong
The	care	plan	for	women	with	PAS	disorders	should	include	logistic	support	for	access	to	blood	
products,	capacity	to	perform	complex	pelvic	surgery,	intensive	care	facilities	(adult	and	neonatal),	
and	obstetric	anesthetists
High Moderate	and	Strong
Surgical	expertise	in	complex	pelvic	surgery	should	be	available	throughout	the	surgical	procedure All Moderate	and	Strong
Scheduled	nonemergent	delivery	is	advisable	for	women	with	PAS	disorders	as	it	is	associated	with	a	
reduction	in	complications	related	to	blood	loss
All Low	and	Strong
Deliberate cystotomy and excision of involved bladder may be considered in cases of percreta villous 
tissue	involving	the	bladder
All Low	and	Strong
A	midline	skin	incision	should	be	considered	for	invasive	PAS	disorders	and	anterior	low-	lying	placenta	
or	previa	accreta	when	the	superior	margin	is	outside	the	lower	uterine	segment
All Low	and	Weak
Where	available,	tranexamic	acid	should	be	administered	(1	g	slow	IV	or	1000–1300	mg	orally)	
immediately	prior	to	or	during	cesarean	delivery	for	PAS	disorders
All High	and	Strong
The	role	of	bilateral	internal	iliac	artery	ligation	at	the	time	of	cesarean	hysterectomy	for	PAS	
disorders is currently unclear
All Low	and	Weak
When	available,	cell	salvage	may	be	utilized	or	be	on	“stand-	by”	during	cases	of	cesarean	delivery	
for	PAS	disorders
High Low	and	Strong
In	the	absence	of	spontaneous	placental	separation,	the	placenta	should	be	left	in	situ	to	minimize	
blood	loss	during	planned	immediate	cesarean	hysterectomy	and	uterotonics	should	not	be	used
All Moderate	and	Strong
Total	hysterectomy	with	placenta	in	situ	is	preferred	over	subtotal	hysterectomy	in	cases	of	
 placenta previa increta or percreta
All Low	and	Strong
In	cases	of	placenta	percreta	with	extensive	pelvic	invasion,	delayed	hysterectomy	with	placenta	
in situ may be considered
High Low	and	Weak
     |  289Allen eT Al.
	20.	 Wright	JD,	Herzog	TJ,	Shah	M,	et	al.	Regionalization	of	care	for	obstet-
ric	hemorrhage	and	its	effect	on	maternal	mortality.	Obstet Gynecol. 
2010;115:194–200.
	21.	 Brookfield	KF,	Goodnough	LT,	Lyell	DJ,	Butwick	AJ.	Perioperative	and	
transfusion	outcomes	in	women	undergoing	cesarean	hysterectomy	
for	abnormal	placentation.	Transfusion. 2014;54:1530–1536.
	22.	 Woldu	SL,	Ordone	MA,	Devin	PC,	Wright	JD.	Urologic	considerations	
of	placenta	accreta:	A	contemporary	tertiary	care	institutional	experi-
ence. Urol Int. 2014;93:74–79.
	23.	 Smulian	JC,	Pascual	AL,	Hesham	H,	et	al.	Invasive	placental	disease:	
The	impact	of	a	multi-	disciplinary	team	approach	to	management.	J 
Matern Fetal Neonatal Med. 2017;30:1423–1427.
	24.	 Silver	RM,	Fox	KA,	Barton	JR,	et	al.	Center	of	excellence	for	placenta	
accreta. Am J Obstet Gynecol. 2015;212:561–568.
	25.	 Brennan	 DJ,	 Schulze	 B,	 Chetty	 N,	 et	 al.	 Surgical	 management	 of	
abnormally	 invasive	placenta:	A	 retrospective	 cohort	 study	demon-
strating	 the	 benefits	 of	 a	 standardized	 operative	 approach.	 Acta 
Obstet Gynecol Scand. 2015;94:1380–1386.
	26.	 Green	L,	Knigh	M,	Seeney	F,	et	al.	The	haematological	features	and	
transfusion	management	of	women	who	required	massive	transfusion	
for	major	obstetric	haemorrhage	in	the	UK:	A	population	based	study.	
Br J Haematol. 2016;172:616–624.
	27.	 Shamshirsaz	 AA,	 Fox	 KA,	 Erfani	 H,	 et	 al.	 Multidisciplinary	 team	 
learning	 in	 the	 management	 of	 the	 morbidly	 adherent	 placenta:	
Outcome	 improvements	over	time.	Am J Obstet Gynecol. 2017;216: 
612.e1–612.e5.
	28.	 Bowman	ZS,	Manuck	TA,	Eller	AG,	Simon	M,	Silver	RM.	Risk	factors	
for	 unscheduled	 delivery	 in	 patients	 with	 placenta	 accreta.	 Am J 
Obstet Gynecol. 2014;210:241.e1–241.e6.
	29.	 Rac	MW,	Wells	CE,	Twickler	DM,	Moschos	E,	McIntire	DD,	Dashe	JS.	
Placenta	accreta	and	vaginal	bleeding	according	to	gestational	age	at	
delivery. Obstet Gynecol. 2015;125:808–813.
	30.	 Robinson	 BK,	 Grobman	WA.	 Effectiveness	 of	 timing	 strategies	 for	
delivery	 of	 individuals	 with	 placenta	 previa	 and	 accreta.	 Obstet 
Gynecol. 2010;116:835–842.
	31.	 Breymann	 C,	Milman	N,	Mezzacasa	A,	 Bernard	 R,	 Dudenhausen	 J;	
FER-ASAP	 Investigators.	 Ferric	 carboxymaltose	 vs.	 oral	 iron	 in	 the	
treatment	of	pregnant	women	with	iron	deficiency	anemia:	An	inter-
national,	open-	label,	randomized	controlled	trial	(FER-	ASAP).	J Perinat 
Med. 2017;45:443–453.
	32.	 Wong	 L,	 Smith	 S,	 Gilstrop	 M,	 et	 al.	 Safety	 and	 efficacy	 of	 rapid	
(1,000	mg	in	1	hr)	intravenous	iron	dextran	for	treatment	of	maternal	
iron	deficient	anemia	of	pregnancy.	Am J Hematol. 2016;91:590–593.
	33.	 Tam	Tam	KB,	Dozier	J,	Martin	JN	Jr.	Approaches	 to	 reduce	urinary	 
tract injury during management of placenta accreta, increta, and per-
creta:	 A	 systematic	 review.	 J Matern Fetal Neonatal Med. 2012;25: 
329–334.
	34.	 Abbas	F,	Talati	J,	Wasti	S,	Akra	S,	Ghaffar	S,	Qureshi	R.	Placenta	per-
creta	with	bladder	invasion	as	a	cause	of	life	threatening	hemorrhage.	
J Urol. 2000;164:1270–1274.
	35.	 Matsubara	S,	Kuwata	T,	Usui	R,	et	al.	Important	surgical	measures	and	
techniques	at	cesarean	hysterectomy	for	placenta	previa	accreta.	Acta 
Obstet Gynecol Scand. 2013;92:372–377.
	36.	 Belfort	MA,	Shamshirsaz	AA,	Fox	KA.	A	technique	to	positively	iden-
tify	 the	 vaginal	 fornices	 during	 complicated	 postpartum	 hysterec-
tomy. Am J Obstet Gynecol. 2017;217:222.e1–222.e3.
	37.	 Ioscovich	 A,	 Shatalin	 D,	 Butwick	 AJ,	 Ginosar	 Y,	 Orbach-Zinger	 S,	
Weiniger	CF.	Israeli	survey	of	anesthesia	practice	related	to	placenta	
previa and accreta. Acta Anaesthesiol Scand. 2016;60:457–464.
	38.	 Iwata	A,	Murayama	Y,	Itakura	A,	Baba	K,	Seki	H,	Takeda	S.	Limitations	
of	 internal	 iliac	 artery	 ligation	 for	 the	 reduction	 of	 intraoperative	
hemorrhage	during	cesarean	hysterectomy	in	cases	of	placenta	previa	
accreta. J Obstet Gynaecol Res. 2010;36:254–259.
	39.	 Lilker	SJ,	Meyer	RA,	Downey	KN,	Macarthur	AJ.	Anesthetic	consider-
ations	for	placenta	accreta.	Int J Obstet Anesth. 2011;20:288–292.
	40.	 Taylor	NJ,	Russell	R.	Anaesthesia	for	abnormally	invasive	placenta:	A	
single-	institution	case	series.	Int J Obstet Anesth. 2017;30:10–15.
	41.	 Munoz	LA,	Mendoza	GJ,	Gomez	M,	Reyes	LE,	Arevalo	JJ.	Anesthetic	
management	 of	 placenta	 accreta	 in	 a	 low-	resource	 setting:	A	 case	
series. Int J Obstet Anesth. 2015;24:329–334.
	42.	 Kocaoglu	 N,	 Gunusen	 I,	 Karaman	 S,	 Ergenoglu	 AM,	 Firat	 V.	
Management	of	anesthesia	 for	cesarean	section	 in	parturients	with	
placenta	previa	with/without	placenta	accreta:	A	retrospective	study.	
Ginekol Pol. 2012;83:99–103.
	43.	 Nguyen-Lu	N,	Carvalho	JC,	Kingdom	J,	Windrim	R,	Allen	L,	Balki	M.	
Mode	 of	 anesthesia	 and	 clinical	 outcomes	 of	 patients	 undergoing	
Cesarean	 delivery	 for	 invasive	 placentation:	A	 retrospective	 cohort	
study	of	50	consecutive	cases.	Can J Anaesth. 2016;63:1233–1244.
	44.	 Hong	JY,	Jee	YS,	Yoon	HJ,	Kim	SM.	Comparison	of	general	and	epi-
dural	anesthesia	in	elective	cesarean	section	for	placenta	previa	tota-
lis:	Maternal	hemodynamics,	blood	loss	and	neonatal	outcome.	Int J 
Obstet Anesth. 2003;12:12–16.
	45.	 Butwick	AJ,	Carvalho	B,	El-Sayed	YY.	Risk	factors	for	obstetric	mor-
bidity	in	patients	with	uterine	atony	undergoing	caesarean	delivery.	Br 
J Anaesth. 2014;113:661–668.
	46.	 Walker	MG,	Pollard	L,	Talati	C,	et	al.	Obstetric	and	anaesthesia	check-
lists	 for	 the	 management	 of	 morbidly	 adherent	 placenta.	 J Obstet 
Gynaecol Can. 2016;38:1015–1023.
	47.	 WOMAN	Trial	Collaborators.	Effect	of	early	tranexamic	acid	admin-
istration	on	mortality,	hysterectomy,	and	other	morbidities	in	women	
with	 post-	partum	 haemorrhage	 (WOMAN):	 An	 international,	 ran-
domised, double- blind, placebo- controlled trial. Lancet. 2017;389: 
2105–2116.
	48.	 Simonazzi	G,	Bisulli	M,	Saccone	G,	Moro	E,	Marshall	A,	Berghella	V.	
Tranexamic	acid	for	preventing	postpartum	blood	loss	after	cesarean	
delivery:	A	systematic	review	and	meta-	analysis	of	randomized	con-
trolled trials. Acta Obstet Gynecol Scand. 2016;95:28–37.
	49.	 Lakshmi	 SD,	 Abraham	 R.	 Role	 of	 prophylactic	 tranexamic	 acid	 in	
reducing	blood	loss	during	elective	caesarean	section:	A	randomized	
controlled study. J Clin Diagn Res. 2016;10:17–21.
	50.	 Ray	I,	Bhattacharya	R,	Chakraborty	S,	Bagchi	C,	Mukhopadhyay	S.	Role	
of	Intravenous	tranexamic	acid	on	caesarean	blood	loss:	A	Prospective	
randomised study. J Obstet Gynaecol India. 2017;66:347–352.
	51.	 Maged	AM,	Helal	OM,	Elsherbin	MM,	et	al.	A	randomized	placebo-	
controlled	trial	of	preoperative	tranexamic	acid	among	women	under-
going	 elective	 cesarean	 delivery.	 Int J Gynecol Obstet. 2015;131: 
265–268.
	52.	 Chou	MM,	Kung	HF,	Hwang	JI,	Chen	WC,	Tseng	JJ.	Temporary	pro-
phylactic	intravascular	balloon	occlusion	of	the	common	iliac	arter-
ies	 before	 cesarean	 hysterectomy	 for	 controlling	 operative	 blood	
loss	 in	 abnormal	 placentation.	 Taiwan J Obstet Gynecol. 2015;54: 
493–498.
	53.	 Luo	F,	Xie	L,	Xie	P,	Liu	S,	Zhu	Y.	Intraoperative	aortic	balloon	occlusion	
in	patients	with	placenta	previa	and/or	placenta	accreta:	A	retrospec-
tive	study.	Taiwan J Obstet Gynecol. 2017;56:147–152.
	54.	 Takahashi	 H,	 Ohkuchi	 A,	 Usui	 R,	 Suzuki	 H,	 Baba	 Y,	 Matsubara	 S.	
Factors	contributing	to	massive	blood	 loss	on	peripartum	hysterec-
tomy	 for	 abnormally	 invasive	 placenta:	 Who	 bleeds	 more?	 Obstet 
Gynecol Int. 2016;2016:5349063.
	55.	 Teixidor	Vinas	M,	Chandraharan	E,	Moneta	MV,	Belli	AM.	The	role	of	
interventional	radiology	in	reducing	haemorrhage	and	hysterectomy	
following	 caesarean	 section	 for	 morbidly	 adherent	 placenta.	 Clin 
Radiol. 2014;69:e345–e351.
	56.	 Ballas	 J,	 Hull	 AD,	 Saenz	 C,	 et	 al.	 Preoperative	 intravascular	 bal-
loon	 catheters	 and	 surgical	 outcomes	 in	 pregnancies	 complicated	
by placenta accreta: A management paradox. Am J Obstet Gynecol. 
2012;207:216.e1–216.e5.
	57.	 Cali	G,	Forlani	F,	Giambanco	L,	et	al.	Prophylactic	use	of	intravascular	
balloon	catheters	 in	women	with	placenta	accreta,	 increta	and	per-
creta. Eur J Obstet Gynecol Reprod Biol. 2014;179:36–41.
290  |     Allen eT Al.
	58.	 Carnevale	FC,	Kondo	MM,	de	Oliveira	Sousa	W	Jr,	et	al.	Perioperative	
temporary	 occlusion	 of	 the	 internal	 iliac	 arteries	 as	 prophylaxis	 in	
cesarean	section	at	risk	of	hemorrhage	in	placenta	accreta.	Cardiovasc 
Intervent Radiol. 2011;34:758–764.
	59.	 D’Souza	 DL,	 Kingdom	 JC,	 Amsalem	 H,	 Beecroft	 JR,	 Windrim	 RC,	
Kachura	 JR.	 Conservative	 management	 of	 invasive	 placenta	 using	
combined	 prophylactic	 internal	 iliac	 artery	 balloon	 occlusion	 and	
immediate	 postoperative	 uterine	 artery	 embolization.	 Can Assoc 
Radiol. 2015;66:179–184.
	60.	 Duan	 XH,	Wang	 YL,	 Han	 XW,	 et	 al.	 Caesarean	 section	 combined	
with	 temporary	 aortic	balloon	occlusion	 followed	by	uterine	 artery	
embolisation	 for	 the	 management	 of	 placenta	 accreta.	 Clin Radiol. 
2015;70:932–937.
	61.	 Kidney	DD,	Nguye	AM,	Ahdoot	D,	Bickmore	D,	Deutsch	LS,	Majors	
C.	Prophylactic	perioperative	hypogastric	artery	balloon	occlusion	in	
abnormal	placentation.	Am J Roentgenol. 2001;176:1521–1524.
	62.	 Dubois	 J,	Garel	 L,	Grignon	A,	 Lema	M,	 Leduc	 L.	 Placenta	 percreta:	
Balloon	 occlusion	 and	 embolization	 of	 the	 internal	 iliac	 arter-
ies	 to	 reduce	 intraoperative	 blood	 losses.	 Am J Obstet Gynecol. 
1997;176:723–726.
	63.	 Minas	 V,	 Gul	 N,	 Shaw	 E,	 Mwenenchanya	 S.	 Prophylactic	 balloon	
occlusion	of	 the	common	 iliac	arteries	 for	 the	management	of	 sus-
pected	 placenta	 accreta/percreta:	 Conclusions	 from	 a	 short	 case	
series. Arch Gynecol Obstet. 2015;291:461–465.
	64.	 Mok	M,	Heidemann	B,	Dundas	K,	Gillespie	I,	Clark	V.	Interventional	
radiology	in	women	with	suspected	placenta	accreta	undergoing	cae-
sarean	section.	Int J Obstet Anesth. 2008;17:255–261.
	65.	 Panici	 PB,	 Anceschi	 M,	 Borgia	ML,	 et	 al.	 Intraoperative	 aorta	 bal-
loon	occlusion:	Fertility	preservation	in	patients	with	placenta	previa	
accreta/increta. J Matern Fetal Neonatal Med. 2012;25:2512–2516.
	66.	 Shih	JC,	Liu	KL,	Shyu	MK.	Temporary	balloon	occlusion	of	the	com-
mon	 iliac	 artery:	 New	 approach	 to	 bleeding	 control	 during	 cesar-
ean	 hysterectomy	 for	 placenta	 percreta.	 Am J Obstet Gynecol. 
2005;193:1756–1758.
	67.	 Sivan	E,	Spira	M,	Achiron	R,	et	al.	Prophylactic	pelvic	artery	cathe-
terization	and	embolization	 in	women	with	placenta	accreta:	Can	 it	
prevent	cesarean	hysterectomy?	Am J Perinatol. 2010;27:455–461.
	68.	 Tan	CH,	Tay	KH,	Sheah	K,	et	al.	Perioperative	endovascular	 internal	
iliac artery occlusion balloon placement in management of placenta 
accreta. Am J Roentgenol. 2007;189:1158–1163.
	69.	 Salim	R,	Chulski	A,	Romano	S,	Garmi	G,	Rudin	M,	Shalev	E.	Precesarean	
prophylactic	balloon	catheters	for	suspected	placenta	accreta:	A	ran-
domized controlled trial. Obstet Gynecol. 2015;126:1022–1028.
	70.	 Bodner	 LJ,	 Nosher	 JL,	 Gribbin	 C,	 Siegel	 RL,	 Beale	 S,	 Scorza	 W.	
Balloon-	assisted	occlusion	of	 the	 internal	 iliac	arteries	 in	patients	
with	 placenta	 accreta/percreta.	 Cardiovasc Intervent Radiol. 
2006;29:354–361.
	71.	 Shrivastava	V,	Nageotte	M,	Majo	C,	Haydo	M,	Wing	D.	Case-	control	
comparison	of	cesarean	hysterectomy	with	and	without	prophylactic	
placement	of	intravascular	balloon	catheters	for	placenta	accreta.	Am 
J Obstet Gynecol. 2007;197:402.e1–402.e5.
	72.	 Levine	AB,	Kuhlman	K,	Bonn	J.	Placenta	accreta:	Comparison	of	cases	
managed	with	and	without	pelvic	artery	balloon	catheters.	J Matern 
Fetal Med. 1999;8:173–176.
	73.	 Clausen	C,	Stensballe	J,	Albrechtse	CK,	Hanse	MA,	Lonn	L,	Langhoff-
Roos	J.	Balloon	occlusion	of	the	internal	iliac	arteries	in	the	multidis-
ciplinary management of placenta percreta. Acta Obstet Gynecol Scan. 
2013;92:386–391.
	74.	 Sentilhes	L,	Goffinet	F,	Kayem	G.	Management	of	placenta	accreta.	
Acta Obstet Gynecol Scand. 2013;92:1125–1134.
	75.	 Greenberg	 JI,	 Suliman	 A,	 Iranpou	 P,	 Angle	 N.	 Prophylactic	 
balloon	 occlusion	 of	 the	 internal	 iliac	 arteries	 to	 treat	 abnormal	
placentation:	 A	 cautionary	 case.	Am J Obstet Gynecol. 2007;197: 
470.e1–470.e4.
	76.	 Sewell	MF,	Rosenblum	D,	Ehrenberg	H.	Arterial	embolus	during	com-
mon	 iliac	 balloon	 catheterization	 at	 cesarean	 hysterectomy.	Obstet 
Gynecol. 2006;108:746–748.
	77.	 Teare	J,	Evans	E,	Belli	A,	Wendler	R.	Sciatic	nerve	ischaemia	after	iliac	
artery	occlusion	balloon	catheter	placement	for	placenta	percreta.	Int 
J Obstet Anesth. 2014;23:178–181.
	78.	 Chouliaras	S,	Hickling	DJ,	Tuck	JS.	Thromboembolism	of	the	leg	fol-
lowing	prophylactic	balloon	occlusion	of	the	uterine	arteries.	BJOG. 
2009;116:1278–1279.
	79.	 Gagnon	 J,	 Boucher	 L,	 Kaufman	 I,	 Brown	 R,	 Moore	 A.	 Iliac	 artery	
rupture	 related	 to	 balloon	 insertion	 for	 placenta	 accreta	 causing	
maternal	 hemorrhage	 and	 neonatal	 compromise.	 Can J Anaesth. 
2013;60:1212–1217.
	80.	 Bishop	S,	Butler	K,	Monaghan	S,	Chan	K,	Murphy	G,	Edozie	L.	Multiple	
complications	 following	 the	use	of	 prophylactic	 internal	 iliac	 artery	
balloon	catheterisation	in	a	patient	with	placenta	percreta.	Int J Obstet 
Anesth. 2011;20:70–73.
	81.	 Matsueda	S,	Hidaka	N,	Kondo	Y,	Fujiwara	A,	Fukushima	K,	Kato	K.	
External	iliac	artery	thrombosis	after	common	iliac	artery	balloon	occlu-
sion	 during	 cesarean	 hysterectomy	 for	 placenta	 accreta	 in	 cervico-	
isthmic	pregnancy.	J Obstet Gynaecol Res. 2015;41:1826–1830.
	82.	 Dilauro	MD,	Dason	 S,	Athreya	 S.	 Prophylactic	 balloon	 occlusion	 of	
internal	 iliac	 arteries	 in	 women	 with	 placenta	 accreta:	 Literature	
review and analysis. Clin Radiol. 2012;67:515–520.
	83.	 Neb	 H,	 Zacharowski	 K,	 Meybohm	 P.	 Strategies	 to	 reduce	 blood	
product	 utilization	 in	 obstetric	 practice.	 Curr Opin Anaesthesiol. 
2017;30:294–299.
	84.	 McDonnell	NJ,	Kennedy	D,	Long	LJ,	Gallagher-Swann	MC,	Paech	MJ.	
The	development	and	implementation	of	an	obstetric	cell	salvage	ser-
vice. Anaesth Intensive Care. 2010;38:492–499.
	85.	 Elagamy	A,	Abdelaziz	A,	Ellaithy	M.	The	use	of	cell	salvage	in	women	
undergoing	 cesarean	 hysterectomy	 for	 abnormal	 placentation.	 Int J 
Obstet Anesth. 2013;22:289–293.
	86.	 Lew	E,	Tagore	S.	Implementation	of	an	obstetric	cell	salvage	service	in	
a	tertiary	women’s	hospital.	Singapore Med J. 2015;56:445–449.
	87.	 Albright	CM,	Rouse	DJ,	Werner	EF.	Cost	savings	of	red	cell	salvage	
during cesarean delivery. Obstet Gynecol. 2014;124:690–696.
	88.	 Esper	SA,	Waters	JH.	Intra-	operative	cell	salvage:	A	fresh	look	at	the	
indications	and	contraindications.	Blood Transfus. 2011;9:139–147.
	89.	 Weiniger	CF,	Kabiri	D,	Ginosar	Y,	Ezra	Y,	Shachar	B,	Lyell	DJ.	Suspected	
placenta	 accreta	 and	 cesarean	 hysterectomy:	Observational	 cohort	
utilizing	 an	 intraoperative	 decision	 strategy.	 Eur J Obstet Gynecol 
Reprod Biol. 2016;198:56–61.
	90.	 Belfort	MA,	Shamshiraz	AA,	Fox	K.	Minimizing	blood	loss	at	cesarean-	
hysterectomy	 for	 placenta	 previa	 percreta.	 Am J Obstet Gynecol. 
2017;216:78.e1–78.e2.
	91.	 Rossetti	D,	Vitale	SG,	Bogani	G,	Rapisarda	AM,	Gulino	FA,	Frigerio	L.	
Usefulness	of	vessel-	sealing	devices	for	peripartum	hysterectomy:	A	
retrospective	cohort	study.	Updates Surg. 2015;67:301–304.
	92.	 Arendas	K,	Lortie	KJ,	Singh	SS.	Delayed	laparoscopic	management	of	
placenta increta. J Obstet Gynaecol Can. 2012;34:186–189.
	93.	 Smith	DD,	Perez-Delboy	A,	Burke	WM,	Tergas	AI.	Buttock	necrosis	
after	 uterine	 artery	 embolization	 for	 delayed	 hysterectomy	 in	 pla-
centa percreta. Case Rep Obstet Gynecol. 2016;2016:6921280.
	94.	 Rupley	DM,	Tergas	AI,	Palmerola	KL,	Burke	WM.	Robotically	assisted	
delayed	 total	 laparoscopic	 hysterectomy	 for	 placenta	 percreta.	
Gynecol Oncol Rep. 2016;17:53–55.
	95.	 Skinner	 BD,	 Golichowski	 AM,	 Raff	 GJ.	 Laparoscopic-	assisted	
vaginal	 hysterectomy	 in	 a	 patient	 with	 placenta	 percreta.	 JSLS. 
2012;16:143–147.
	96.	 Ochalski	ME,	Broach	A,	Lee	T.	Laparoscopic	management	of	placenta	
percreta. J Minim Invasive Gynecol. 2010;17:128–130.
	97.	 Selman	AE.	Caesarean	hysterectomy	for	placenta	praevia/accreta	using	
an	approach	via	the	pouch	of	Douglas.	BJOG. 2016;123:815–819.
